Position in NVS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$288,678
-$1,547 QoQ
Shares Held
1,842
-3.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,150
of 1,603 holders
Holding Since
Jun 2023
8 quarters on record
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Empower Advisory Group, LLC holds $946,768,864 across 11 Drug Manufacturers - General names. NVS ranks #10 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
268,075 | $321,537,224 | |
| 2 | JNJ |
Johnson & Johnson
|
905,317 | $229,923,358 | |
| 3 | ABBV |
AbbVie Inc.
|
507,376 | $127,676,096 | |
| 4 | AMGN |
Amgen Inc
|
349,667 | $126,621,414 | |
| 5 | PFE |
Pfizer Inc
|
4,830,581 | $116,320,390 | |
| 6 | MRK |
Merck & Co., Inc.
|
169,726 | $21,809,791 | |
| 7 | AZN |
Astrazeneca PLC
|
5,682 | $1,077,420 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
7,129 | $900,677 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $288,678 | 1,842 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $290,225 | 1,900 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $318,479 | 2,310 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $241,091 | 1,880 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $257,072 | 2,306 | Shares | Sole | 2025-05-09 | |
| 2023-12-31 | $204,969 | 2,030 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $265,752 | 2,609 | Shares | Sole | 2023-11-06 | |
| 2023-06-30 | $201,517 | 1,997 | Shares | Sole | 2023-08-10 | |
| No filing history on record for this holder in this stock. | ||||||